These patients are doing a cost-benefit study of sorts. In the case of chemotherapy drugs, they point out that, unlike most drugs, which have a high risk of benefit but also a chance of damage, many anticancer drugs have a high chance of harm but only a chance of benefit. The treatments can extend life, but for how long? And how much would it cost? There has been no research because withdrawing care from a control group would be unethical, but a study comparing nearly 800 patients who declined all traditional cancer treatment to those who approved treatment showed that rejection cut median survival time by nine months.Do you want to learn more?check it out
The study’s scope was broad: participants had 30 different types of cancer at various stages of the disease, with survival ranging from two months to more than six years. But the point is that therapy will buy you a lot of time in some cases and not in others. As a result, and as shown by studies, older patients decline care more often than younger patients. They sometimes claim that they have lived their lives or that the possibility of a little more time alive does not warrant the risks associated with treatment. In one study of women with breast cancer, 7% of those aged 65 and up declined care, compared to 3% of those aged under 65. Prostate cancer in older men is often delayed due to concerns about side effects such as incontinence and impotence, and in fact, waiting and monitoring PSA levels is often a doctor-approved choice. However, in most cases, a patient is not given enough information or time to consider their choices, which is a common concern among proponents of complementary and alternative medicine. Refuseniks are generally intelligent, articulate, and well-aware of the potential implications of their behaviour.